Email :
info@xynomicpharma.com
Latest News
Y. Mark Xu talks with CGTN (China Global TV Network)
Mark Xu, Founder, Chairman, Chief Executive Officer and President of Xynomic talks with CGTN “The Point with Liu Xin” and provides insight regarding the current trend of the price of cancer drugs in China. “The
Details
Bison Capital Acquisition Corp. and Xynomic Pharmaceuticals, Inc. Announce Signing of Definitive Merger Agreement
NEW YORK, NY and SHANGHAI, China, Sept. 12, 2018 (GLOBE NEWSWIRE) –– Bison Capital Acquisition Corp. (“BCAC”, NASDAQ: BCAC) and Xynomic Pharmaceuticals, Inc. (“Xynomic”), a U.S.-China clinical stage innovative oncology drug development company, today jointly
Details
Mark Xu ( Chairman and CEO of Xynomic ) Invited to Participate in JP Morgan Healthcare Conference
The annual J.P. Morgan Healthcare Conference is the largest and most informative healthcare investment symposium in the industry, bringing together industry leaders, emerging fast-growth companies, innovative technology creators, and members of the investment community.
Xynomic Pharma Initiates Ph 1/2 Trial Combining Abexinostat with Ibrutinib in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (r/r DLBCL) and Mantle Cell Lymphoma (r/r MCL)
CHEYENNE, Wyo., Dec. 1, 2017 /PRNewswire/ — Xynomic Pharma, a clinical stage US oncology drug development company, today announced that it will initiate a Ph 1/2 trial, in collaboration with Janssen R&D, LLC (Janssen Pharmaceutical Companies of
Details
Xynomic Pharma Acquires Global Rights of Boehringer Ingelheim’s BI 882370, a Novel and Potent RAF Inhibitor against Solid Tumors
CHEYENNE, Wyo., Oct. 30, 2017 /PRNewswire/ — Xynomic Pharma, a clinical stage US oncology drug development company, today announced that it has acquired exclusive global rights to develop, manufacture and commercialize BI 882370, a 2nd-generation RAF inhibitor,
Details
Xynonic Invited to Present at the Prestigious Berstein China Oncology Day in Hong Kong on June 21
Mr. Y. Mark Xu, Chairman, CEO and President, has been invited to speak at this high profile conference. Other presenting companies include Roche, Sanofi, Hengrui and Sino Biopharm. The venue is Mandarin Oriental Hotel, Hong
Details
Xynomic Pharma and UCSF Entered Strategic Partnership in Conducting a Phase 2/3 Trial of Abexinostat against Renal Cell Carcinoma
CHEYENNE, Wyo., May 22, 2017 /PRNewswire/ — Xynomic Pharma, a clinical stage US oncology drug R&D company, today announced that it has entered into a strategic partnership with the University of California San Francisco (“UCSF”) to conduct
Details
Abexinostat Significantly Reversed Treatment Resistance in GSK’s Pazopanib- and other VEGF inhibitor-refractory Tumors in a 51-Patients Ph 1b Trail Led by Professor Munster at UCSF
Sponsored by NCI and UCSF 51 patients (72% had received two or more lines of therapy in the locally advanced or metastatic setting), Phase 1b, open-label, dose-escalation/expansion trial of Abexinostat in combination with GSK’s pazopanib
Details
Xynomic Pharma has acquired Greater China rights to a novel ACAT-1 inhibitor for cancer indications
March. 8, 2017 — Xynomic Pharmaceuticals, Inc., a US-China oncology startup, has acquired Greater China rights to a novel ACAT-1 inhibitor for cancer indications from Resarci Therapeutics of West Lafayette, Indiana. It will be tested
Details
Xynomic Pharma Has Acquired Worldwide Rights of Abexinostat
CHEYENNE, Wyoming, Feb. 24, 2017 /PRNewswire/ — Xynomic Pharmaceuticals, Inc., an oncology drug research and development company, today announced that it has acquired exclusive worldwide rights to develop, manufacture and commercialize Abexinostat, a potentially best-in-class
Details